Best Way to Pay Clinical Trial Subjects: Sponsor Guide
- ccerqueda
- 12 hours ago
- 11 min read
Participant payments are part of the study experience, not a back-office detail. Sponsors and research organisations must make payments clear to participants, appropriate to the approved protocol. Practical across countries, and manageable for the teams responsible for approvals, reporting, and support.
The best way to pay clinical trial subjects is a payment programme that matches the purpose and timing of each payment to participant access, study oversight, and operational controls. It may use one or more payout rails, but the stronger decision starts with governance and participant needs rather than a particular card, wallet, or transfer method.
This guide focuses on the decision framework behind a participant payment programme. It does not repeat a product-level prepaid-card comparison. For a detailed discussion of prepaid cards as one possible participant payout tool, see Intercash's guide to prepaid cards for clinical trial participants.
What is the best way to pay clinical trial subjects?
There is no universal payment rail that works for every clinical trial. The best approach is the one that supports the approved study design and works for the actual participant population. That means considering why the participant is being paid, when the payment is due, how the participant can access funds, and how the sponsor will evidence each transaction.
Payment design should be separated into two connected decisions. First, define the payment type, such as reimbursement for an approved expense, compensation for time or inconvenience, or a stipend covering a defined set of study-related needs. Second, select the delivery model that can execute that design across the relevant countries and sites. This distinction prevents teams from choosing technology before they know what the payment must accomplish.
Use a programme decision, not a channel decision
A channel decision asks whether a sponsor should use a bank transfer, cheque, cash, wallet, card, or another rail. A programme decision asks whether the entire process is clear, approved, accessible, traceable, and supportable. The second question is more useful because the same rail can perform differently across countries, participant groups, and study phases.
For example, a participant may be able to receive a digital payment in one market but prefer a physical option in another. A site may manage occasional local reimbursements well, but struggle to maintain consistent records across hundreds of recurring visits. A sponsor may have an approved compensation schedule, but lack a central way to identify failed payments and unresolved participant questions. These are programme issues, not isolated transaction issues.
Five tests for a sound payment model
- Purpose:
Can the sponsor explain exactly what each payment covers?
- Approval:
Does the amount, method, timing, and completion treatment align with the relevant study review?
- Access:
Can participants in the intended markets receive and use funds without unreasonable friction?
- Control:
Can authorised teams manage issuance, approvals, exceptions, and support through a defined workflow?
- Evidence:
Can finance, study operations, and oversight teams reconcile what was approved, delivered, and used?
If the answer to any of these questions is unclear, changing the payment rail alone will not solve the underlying problem. The sponsor should first clarify the operating model, then select the tools and partners that support it.
How should sponsors define participant payment types?
The purpose of a payment should be documented before the delivery method is selected. Reimbursement, compensation, and stipends can appear together in one trial, but they are not interchangeable. Treating them as one category can make participant communications vague and make approvals, reporting, and reconciliation harder to manage.
Reimbursement for approved participant expenses
Reimbursement is generally tied to an eligible cost associated with participation. Travel, parking, lodging, meals, or other approved expenses may be handled through an expense policy. The process should state what evidence is required, who reviews it, when the payment becomes due, and how an exception is resolved.
A reimbursement workflow should also account for timing. Participants may need to pay an expense before they receive funds back. Long delays can create avoidable pressure, especially when visits involve travel or repeated out-of-pocket costs. The sponsor should therefore set a clear service expectation for reviewing and releasing approved reimbursements, subject to the study's procedures and local requirements.
Compensation for time, effort, or inconvenience
Compensation recognises participation-related effort. Depending on the approved design, it may relate to a visit, activity, time commitment, inconvenience, or missed work. The participant-facing explanation should use plain language and distinguish compensation from expense reimbursement.
Payment schedules should be mapped to defined milestones. A sponsor needs to know what event makes a payment payable, what happens when a visit is rescheduled, and how the team handles a participant who withdraws. These rules should not be improvised by individual sites. A central policy with documented exception handling helps keep participant treatment consistent.
Stipends and combined support
A stipend may combine several approved elements into a defined amount. It can be useful when a study has a repeated schedule or when a straightforward participant explanation is preferable to several separate expense categories. The sponsor must still document what the stipend represents and how it relates to the approved study materials.
Clear payment categories also improve reporting. When the payment purpose is recorded separately from the payout rail. The sponsor can assess whether a delayed reimbursement, failed compensation payment, or unresolved stipend exception is a study-operations issue. That is more actionable than a report showing only that a transaction was attempted.
What should IRB and study governance review?
Participant payment is connected to ethics and study governance. In the United States, FDA guidance says an Institutional Review Board should review the amount, method, and timing of payment to research subjects. The guidance also addresses undue influence and the treatment of payment when a participant does not complete the entire study. Read the FDA guidance on payment and reimbursement to research subjects for the applicable framework.
This article is operational guidance, not legal or regulatory advice. Requirements vary by study, country, sponsor, institution, and oversight body. Sponsors and CROs should confirm the applicable position with the responsible IRB, ethics committee, legal advisers, tax advisers, and other qualified professionals.
Review the payment plan as part of the study design
The review package should make the payment logic understandable. It should explain the payment purpose, amount or calculation approach, timing, method, participant communications, and treatment of expenses. It should also state what happens when a participant changes location, misses a visit, withdraws, or needs an alternative access route.
FDA guidance indicates that payment should not be entirely contingent on completing the whole study. A small completion incentive may be acceptable when it is not coercive. But the sponsor should not use a completion condition to erase payment for eligible work already completed. If circumstances create a proposed payment that is not addressed in the approved materials, the sponsor may need the appropriate review before proceeding.
Keep payment language consistent across documents
Informed-consent materials, site instructions, participant communications, finance procedures, and payment-system rules should describe the same structure. Inconsistent language creates questions at the point when participants need confidence. It can also lead to site-level interpretations that are difficult to reconcile later.
A useful control is a payment matrix that connects each payment event to its purpose, approval owner, evidence, expected timing, participant message, and delivery route. The matrix does not replace the protocol or review process. It translates the approved design into operating instructions that study and finance teams can use.
How can sponsors design a payment workflow for repeated visits?
Repeated visits introduce a different challenge from a one-time payout. The sponsor must maintain a reliable sequence from participant eligibility to approval, disbursement, notification, reconciliation, and support. A process that depends on email chains and manual spreadsheets can become difficult to control as the number of sites, countries, and payment events grows.
Map the payment event from approval to participant access
- Confirm eligibility:
identify the visit, activity, or expense that makes the participant payment payable.
- Validate the record:
check the required participant, site, expense, and approval information under the study's procedures.
- Authorise the payout:
route the payment through the designated approval owner and preserve the relevant evidence.
- Deliver funds:
use the approved participant-facing route and communicate what was released and when.
- Monitor exceptions:
track failed delivery, missing information, replacement needs, participant questions, and other unresolved cases.
- Reconcile:
match approved events to released funds, returns, adjustments, and final reporting.
This sequence gives each team a clear responsibility. Study operations can confirm the event. Finance can approve and reconcile. Programme operations can manage delivery and exceptions. Participant support can answer questions without asking the participant to repeat the entire history of a payment.
Design for exceptions before launch
Common exceptions include a changed address, an incorrect bank detail, a failed transfer, an unclaimed physical card. A lost card, a participant moving between countries, or a payment that requires additional review. The sponsor should define who owns each exception and what evidence is required to close it.
Exception design is especially important for international studies. A participant may have different access needs from another participant in the same protocol. Country coverage, currency handling, local payment availability, identification requirements, delivery logistics, and participant support should be tested before rollout. The programme should provide an approved path for alternatives rather than leaving sites to create their own solutions.
When does a payout partner improve clinical trial operations?
A sponsor or CRO may be able to build some payment processes internally. The question is whether the internal team wants to own the issuing relationships, compliance operations, participant-facing tools, payment monitoring, and support infrastructure as the study footprint grows.
A specialist payout partner can help when the programme needs a repeatable operating layer behind the study team. The right partner should be assessed on the complete service model, not only on whether it can send a payment. Ask how it supports onboarding, identity checks, approval workflows, reporting, exception handling, participant access, and the countries in scope.
Look for infrastructure that supports the whole chain
Intercash provides white-label card-issuing and payout infrastructure to businesses. It does not sell consumer cards directly to clinical trial participants. Instead, it can support a sponsor's or programme owner's participant payment model through issuing partnerships, programme management, and controlled payout tools.
For an approved card-based programme, Intercash's PrepaidGate merchant back office supports issuance management, balance monitoring, transaction history, reporting, and fraud monitoring. CardPortal gives participants access to card information and transaction visibility through a participant-facing portal and mobile app. The appropriate product configuration depends on the study design, markets, participant needs, and applicable requirements.
Intercash's Cards-as-a-Service model is designed to provide the issuing chain through established issuing-bank relationships, ready BINs, card-network access, and programme management. This can help a business avoid building every component of card infrastructure in-house. It does not remove the sponsor's responsibility for study governance, participant communications, or jurisdiction-specific review.
Assess compliance and operational ownership
Payment infrastructure should have a clear ownership model. Ask which party handles KYC or KYB processes, AML monitoring, PCI DSS responsibilities, fraud monitoring, participant support, reporting, and regulatory coordination. Also confirm which activities remain with the sponsor, CRO, site, or employer of record.
A credible operating model makes these boundaries explicit. It should show where study data enters the process, which team can approve a payout. How a participant is notified, what information is retained, and how an exception is escalated. The goal is not to transfer all responsibility to a provider. The goal is to make responsibility visible and workable.
How should global participant payments be tested before launch?
A global payment programme should be tested as a participant experience and an operating process. A successful test is not only a transaction that reaches a destination. It also shows that the participant can understand the payment, access funds, obtain support, and receive a resolution when something goes wrong.
Run a market and participant access review
List every country, currency, site, and participant group in the initial scope.
Confirm the permitted payout routes and the practical access requirements in each market.
Identify participants who may need physical delivery, a digital route, language support, or an alternative process.
Document onboarding, identity, delivery, activation, replacement, and support steps.
Test failed payments and unresolved cases, not only successful payments.
Participant optionality can be valuable, but it should be designed rather than promised broadly. If a participant can choose among approved routes, the sponsor needs a consistent way to record that choice, explain the implications, and support the selected method. If only one route is available in a market, the participant communication should be clear before enrolment or the relevant payment event.
Test reporting and reconciliation with realistic events
Finance and study operations should test recurring visits, partial completion, approved reimbursements, declined payments, replacements, adjustments, and returns. Reports should show enough detail to answer practical questions without exposing information to teams that do not need it.
The test should also confirm the handoff between systems. If the sponsor uses a clinical trial management system, expense workflow, finance platform, or custom API, identify the source of truth for each field. Intercash supports programme integration through APIs, but the sponsor remains responsible for defining the data flow, permissions, retention, and reconciliation rules that fit the study.
A short pilot can expose issues that a desktop review will miss. Use representative participant scenarios, countries, payment purposes, and support questions. Record the findings and resolve material gaps before a wider rollout.
What should sponsors include in a participant payment checklist?
The following checklist can help a sponsor or CRO turn the payment decision into an accountable operating plan. It is intentionally focused on programme readiness rather than ranking one payment method above another.
- Payment purpose:
reimbursement, compensation, stipend, or another approved category is defined.
- Study alignment:
the amount, method, timing, and completion treatment are aligned with the applicable protocol and review.
- Participant communication:
participants can understand what is paid, when it is paid, and how to request help.
- Market coverage:
countries, currencies, participant access, delivery, and local requirements are assessed.
- Approval workflow:
eligibility, evidence, authorisation, and exception ownership are documented.
- Control environment:
identity, AML, fraud, data, security, and reporting responsibilities are assigned.
- Operational tools:
the sponsor can monitor payment status, balances or transactions where relevant, failures, and open cases.
- Reconciliation:
released funds can be matched to approved events and adjustments.
- Support:
participants and sites have a defined route for questions, replacements, and disputes.
- Scale:
the model can support expected study volume without creating uncontrolled manual work.
This checklist can also support a partner evaluation. A provider should be able to explain which checklist items it supports, which it shares with the sponsor, and which remain outside its service. That clarity is more useful than a generic promise of fast payments.
For sponsors seeking the best way to pay clinical trial subjects. The strongest answer is usually a documented programme that connects approved payment categories to accessible delivery, visible controls, reliable reporting, and participant support. The payment rail is important, but the operating model determines whether the experience works at scale.
Frequently Asked Questions
How should sponsors choose the best way to pay clinical trial subjects?
Start with the approved payment design, then assess participant access, country coverage, timing, reporting, controls, and support. Define whether each payment is reimbursement, compensation, or a stipend before selecting the delivery route. A single rail may work for one study, while another may need approved options for different markets or participant needs.
What is the difference between reimbursement and compensation?
Reimbursement covers an approved out-of-pocket expense connected with participation. Compensation recognises time, effort, inconvenience, or another defined participation commitment. A stipend may combine several approved elements into a defined amount. Sponsors should document each purpose separately so participant communications, approvals, and reports remain clear.
Does the IRB need to approve the payment method?
For studies subject to FDA oversight, FDA guidance says an Institutional Review Board should review the amount, method, and timing of payment to research subjects. Requirements can vary by study and jurisdiction. Sponsors should confirm the applicable process with the responsible IRB or ethics committee and qualified legal or regulatory advisers.
Should all participant payments depend on completing the study?
No. FDA guidance states that payment should not be entirely contingent on completing the whole study. A small completion incentive may be acceptable when it is not coercive, but eligible visits or activities should be handled under the approved payment structure. If a proposed payment is not addressed in the study materials, the sponsor may need additional review before proceeding.
Can a white-label payout provider support a clinical trial programme?
Yes, a white-label provider can supply infrastructure that a sponsor, CRO, or programme owner uses within its own participant payment experience. The provider should explain its issuing, compliance, reporting, integration, and support responsibilities. It does not replace IRB review, study governance, participant communications, or jurisdiction-specific advice.
Plan a controlled participant payment programme
Choosing the best way to pay clinical trial subjects requires more than comparing transaction types. Sponsors and research organisations need a model that respects the approved study design, supports participants across the intended markets, and gives operational teams the controls and evidence required to manage recurring payouts.
Intercash can discuss a white-label card-issuing and payout model for businesses planning participant disbursements, including the programme-management and cross-border considerations that shape implementation.
